The use and interpretation of competing risks regression models

Clinical Cancer Research

Volumn 18, Issue 8, 2012, Pages 2301-2308

  Dignam, James J ^a,b   Zhang, Qiang ^b   Kocherginsky, Masha ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; ALGORITHM; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CAUSE OF DEATH; CONTROLLED STUDY; COVARIANCE; HAZARD ASSESSMENT; HAZARD RATIO; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK REDUCTION; SIMULATION; STATISTICAL MODEL;

DATA INTERPRETATION, STATISTICAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RISK; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84859842971     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2097     Document Type: Article

References (40)

1. Gelman R, Gelber R, Henderson IC, Coleman CN, Harris JR. Improved methodology for analyzing local and distant recurrence. J Clin Oncol 1990;8:548-55.
2. Korn EL, Dorey FJ. Applications of crude incidence curves. Stat Med 1992;11:813-29.
3. Gaynor JJ, Feuer EJ, Tan CC, Wu DH, Little CR, Straus DJ, et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc 1993;88:400-9.
4. Caplan RJ, Pajak TF, Cox JD. Analysis of the probability and risk of cause-specific failure. Int J Radiat Oncol Biol Phys 1994;29:1183-6. (Pubitemid 24278988)
5. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706. (Pubitemid 29126745)
6. Freidlin B, Korn EL. Testing treatment effects in the presence of competing risks. Stat Med 2005;24:1703-12. (Pubitemid 40754089)
7. Williamson PR, Kolamunnage-Dona R, Tudur Smith C. The influence of competing-risks setting on the choice of hypothesis test for treatment effect. Biostatistics 2007;8:689-94. (Pubitemid 47511797)
8. Dignam JJ, Kocherginsky MN. Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 2008;26:4027-34.
9. Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54. (Pubitemid 9067879)
10. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
11. Bentzen SM, Vaeth M, Pedersen DE, Overgaard J. Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment. . .now! Int J Radiat Oncol Biol Phys 1995;32:1531-4.
12. Caplan RJ, Pajak TF, Cox JD. In response to Bentzen et al., IJROBP 32:1531-1534; 1995.
13. Int J Radiat Oncol Biol Phys 1995;32:1547.
14. Chappell R.: Re: Caplan et al. IJROBP 29:1183-1186; 1994
15. and Bentzen et al. IJROBP 32:1531-1534; 1995.
16. Int J Radiat Oncol Biol Phys 1996;36:988-9.
17. Denham JW, Hamilton CS, O'Brien P. Regarding actuarial late effect analyses: Bentzen et al., IJROBP 32:1531-1534; 1995
18. and Caplan et al., IJROBP 32:1547; 1995.
19. Int J Radiat Oncol Biol Phys 1996;35:197.
20. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007;13:559-65. (Pubitemid 46225362)
21. Tai BC, Grundy R, Machin D. On the importance of accounting for competing risks in pediatric brain cancer: II. Regression modeling and sample size. Int J Radiat Oncol Biol Phys 2011;79:1139-46.
22. Allignol A, Schumacher M, Wanner C, Dreschler C, Beyersmann J. Understanding competing risks: a simulation point of view. BMC Med Res Methodol 2011;11:86.
23. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
24. Slud EV, Byar D. How dependent causes of death can make risk factors appear protective. Biometrics 1988;44:265-9. (Pubitemid 18098829)
25. Di Serio C. The protective impact of a covariate on competing failures with an example from a bone marrow transplantation study. Lifetime Data Anal 1997;3:99-122. (Pubitemid 127479323)
26. Cheng SC, Fine JP, Wei LJ. Prediction of cumulative incidence function under the proportional hazards model. Biometrics 1998;54:219-28. (Pubitemid 28158797)
27. Andersen PK, Borgan O, Gill R, Keiding N. Statistical models based on counting processes. New York: Springer; 1992.
28. Benichou J, Gail MH. Estimates of absolute cause-specific risk in cohort studies. Biometrics 1990;46:813-26. (Pubitemid 20333612)
29. Bryant J, Dignam JJ. Semiparametric models for cumulative incidence functions. Biometrics 2004;60:182-90. (Pubitemid 38392630)
30. Jeong JH, Fine JP. Parametric regression on cumulative incidence function. Biostatistics 2007;8:184-96.
31. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 2005;61:223-9.
32. Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics 2001;2:85-97.
33. Hougaard P. A class of multivariate failure time distributions. Biometrika 1986;73:671-8.
34. Tsiatis AA. A nonidentifiability aspect of the problem of competing risks. Proc Natl Acad Sci U S A 1975;72:20-2.
35. Gail MH. A review and critique of some models used in competing risk analysis. Biometrics 1975;31:209-2.
36. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52. (Pubitemid 32727802)
37. Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed 2008;89:289-300.
38. Latouche A, Boisson V, Chevret S, Porcher R. Misspecified regression model for the subdistribution hazard of a competing risk. Stat Med 2007;26:965-74. (Pubitemid 46291125)
39. Beyersmann J, Schumacher M. Comment on: misspecified regression model for the subdistribution hazard of a competing risk. Stat Med 2007;26:1649-51.
40. Grambauer N, Schumacher M, Beyersmann J. Proportional subdistribution hazards modeling offers a summary analysis, even if misspecified. Stat Med 2010;29:875-84.